Obsidian Therapeutics, Inc.
For the period ended Jun 30, 2026. Filed Aug 14, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 14, 2026
OBX$13.87+44.4%Stored close · as of Nov 6, 2026
Contents
Item 1. Financial Statements (unaudited)
| Condensed Consolidated Balance Sheet at June 30, 2026 | 1 | |
| Condensed Consolidated Statement of Operations and Comprehensive Income for the period April 10, 2026 (Inception) to June 30, 2026 | 2 | |
| Condensed Consolidated Statement of Changes in Shareholder's Equity for the period April 10, 2026 (Inception) to June 30, 2026 | 3 | |
| Condensed Consolidated Statement of Cash Flows for the period April 10, 2026 (Inception) to June 30, 2026 | 4 | |
| Notes to the Condensed Consolidated Financial Statements. | 5 | |
| Item 2. | Management’s Discussion and Analysis of Results of Operations and Financial Condition. | 7 |
|---|---|---|
| Item 4. | Controls and Procedures. | 7 |
| PART II - OTHER INFORMATION | ||
| Item 1A. | Risk Factors. | 8 |
| Item 6. | Exhibits. | 9 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.